All In Biotech

Drug Trial Radar · NCT03022097

Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients

A 24-week Treatment, Randomised, Parallel-group, Double Blinded, Double-Dummy, Multicenter Study to Assess the Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Compared With Individual Components and Placebo and Aclidinium Bromide Compared With Placebo When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.

Last checked: Nov 19, 2026Latest source record: Mar 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,625 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,625

Actual

Start

Feb 2, 2017

Primary completion

Apr 14, 2022

Study completion Apr 14, 2022

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Jan 16, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual components and placebo and Aclidinium bromide compared with Placebo when administered to patients with stable Chronic Obstructive Pulmonary Disease (COPD).

Conditions

  • COPD

Interventions

  • Aclidinium bromide/formoterol Fixed-Dose CombinationDrug

    Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination, twice per day via Genuair

  • Aclidinium bromideDrug

    Inhaled Aclidinium bromide 400 μg, twice per day via Genuair

  • Formoterol FumarateDrug

    Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler

  • PlaceboDrug

    Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1)Time frame: Week 24, 1-hour morning post-dose
  2. Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide/Formoterol FumarateTime frame: Week 24, morning pre-dose (trough)
  3. Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium BromideTime frame: Week 24, morning pre-dose (trough)

Locations

74 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Site

    Baotou, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Cangzhou, China

  • Research Site

    Changchun, China

  • Research Site

    Changsha, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Guangzhou, China

  • Research Site

    Haikou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hefei, China

  • Research Site

    Hefei, China

  • Research Site

    Hefei, China

  • Research Site

    Hengyang, China

  • Research Site

    Hohhot, China

  • Research Site

    Liangyugang, China

  • Research Site

    Linhai, China

  • Research Site

    Nanchang, China

  • Research Site

    Nanjing, China

  • Research Site

    Qiqihar, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanxi, China

  • Research Site

    Shengyang, China

  • Research Site

    Shenzhen, China

  • Research Site

    Shenzhen, China

  • Research Site

    Shijiazhuang, China

  • Research Site

    Taiyuan, China

  • Research Site

    Tianjin, China

  • Research Site

    Wenzhou, China

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.